Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 213

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1A
Chunk 213
---
 
     3,896,199  
     3,896,199 
  
    Accumulated Amortization 
     (3,872,474) 
     (3,866,100)
  
    Patents and trademarks, net 
    $23,725  
    $30,099 

For
the years ended March 31, 2025 and 2024, amortization expenses was $6,374
and $8,550,
respectively. The annual amortization expense will be $6,374 for each of the next three years, from 2026 through 2028, and $4,603
in 2029, whereby the net intangible assets will be fully amortized.

    F-13

NOTE
7 – LICENSING AGREEMENTS

The
components of licensing agreements, all of which are finite-lived, were as follows:

 SCHEDULE
OF LICENSING AGREEMENTS

    March 31, 2025  
    March 31, 2024 
  
     License Agreement 
    $2,000,000  
    $- 
  
    Accumulated Amortization 
     (50,000) 
     - 
  
    Total net 
    $1,950,000  
    $- 

In
February 2025, the Company signed an exclusive licensing agreement with VetStem, Inc. to market and sell their Precise PRP
(Platelet-Rich Plasma) for both canine and equine products. The exclusive licensing agreement is a 5
five-year agreement whereby the Company paid an initial licensing fee of $2,000,000,
which was paid in a combination of $500,000 cash,
$1,000,000 in
stock issuances and $500,000 in
future contract payments, which is included in accrued expenses as of March 31, 2025. The licensing fee will be amortized over sixty
(60)
months, the term of the agreement. The licensing
agreement also has a nominal royalty fee payment between 3%
to 4.5%,
commencing in the seventh month of the licensing agreement. The royalty fee expense for the years ended March 31, 2025 and 2024 were
$0 and $0, respectively. We also issued 250,000 warrants, with a strike price of $1.25 per share for a term of three years.